Key Stats for Regeneron Stock
- 52-Week Range: $476 to $821
- Current Price: $752
- Street Mean Target: $878
- Street High Target: $1,057
- TIKR Model Target (Dec. 2030): $1,248
What Happened?
Regeneron Pharmaceuticals (REGN) is a fully integrated biotech that generates most of its revenue from Dupixent, a blockbuster biologic for atopic dermatitis and eight other Type 2 inflammatory diseases co-commercialized with Sanofi; EYLEA HD, a high-dose anti-VEGF treatment for retinal diseases; and Libtayo, an approved immunotherapy for non-melanoma skin cancers and non-small cell lung cancer.
For months, Regeneron stock carried a company-specific overhang that peers did not: it was the last holdout among 17 major pharmaceutical companies negotiating most-favored-nation drug pricing deals with the Trump administration in exchange for tariff relief.
On April 23, that overhang cleared.
President Trump announced Regeneron had reached an agreement covering Medicaid price reductions aligned with other developed countries, direct-to-patient access through TrumpRx.gov, and a three-year exemption from pharmaceutical tariffs, removing the final headline risk that had kept a ceiling on the stock.
Two days earlier, Regeneron had already delivered the week’s more structurally important result: positive Phase 3 NIMBLE trial data for cemdisiran in generalized myasthenia gravis (gMG), a rare chronic autoimmune disease that causes progressive muscle weakness through complement-mediated injury at the nerve-muscle junction.
Cemdisiran is an siRNA, a genetic medicine that reduces production of C5, the key complement protein driving tissue destruction in this disease, and requires only a subcutaneous injection once every 12 weeks.
In NIMBLE, cemdisiran delivered a 2.3-point placebo-adjusted improvement in the Myasthenia Gravis Activities of Daily Living score at week 24, the best result among approved and investigational C5 inhibitors in this indication, with the leading approved C5 antibody achieving only 1.6 points by comparison.
Regeneron submitted the NDA using a priority review voucher and expects a regulatory decision in Q4 2026, with a potential launch by late 2026 or early 2027, entering a gMG market the company projects will grow to over $12 billion in annual net sales by 2032.
TD Cowen raised its price target on REGN to $960 from $800 and reiterated its buy rating, citing cemdisiran’s best-in-class potential not only in gMG but across a broader C5 platform spanning paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy.
Neither the tariff deal nor the Phase 3 win alone explains why the second half of 2026 is a structural inflection point for Regeneron stock.
The missing piece is the Sanofi development balance: a cost-sharing account that has suppressed Regeneron’s recognized share of DUPIXENT profits for years and is set to reach full repayment by mid-2026, unlocking approximately $1.2 billion in additional annual collaboration revenue on a full-year basis from 2027 forward.
Wall Street’s Take on REGN Stock
The tariff deal resolves the pricing overhang, but the more consequential shift is structural: Regeneron stock enters the second half of 2026 with a materially different earnings profile than it had in the first, and Wall Street is only beginning to price it that way.
Of 29 analysts covering Regeneron stock, 18 rate it buy and 4 outperform, against 7 holds and zero sells, with a mean price target of $878.02 implying 17% upside from current levels and a high target of $1,057 that reflects full pipeline optionality.
The gap between the $730 low target and the $1,057 high maps directly to the debate: analysts at the low end are modeling REGN as a DUPIXENT-and-EYLEA story facing biosimilar pressure, while the high end prices in cemdisiran’s gMG launch, the C5 franchise in PNH and GA, and Lynozyfic’s expansion into earlier lines of multiple myeloma.
Trading at roughly 16.6x 2026 earnings estimates against a historical multiple closer to 20x, with normalized EPS set to grow at roughly 8% annually through 2030 and free cash flow expanding from $4.08 billion in 2025 to around $5 billion in 2026, Regeneron stock appears undervalued for investors willing to hold through the EPS ramp.
The risk is execution timing: EYLEA 2mg biosimilar competition is expected to intensify in H2 2026 as multiple additional products enter the market, requiring EYLEA HD conversion to fully absorb the headwind at a pace that consensus is only partially pricing in.
The catalyst that resolves the debate is the fianlimab plus Libtayo data in first-line metastatic melanoma, expected in H1 2026, which TD Cowen and others see as the readout with the potential to make Regeneron a credible oncology compounder alongside its immunology and ophthalmology franchises.
What Does the Valuation Model Say?
TIKR’s mid-case model targets $1,579.92 for Regeneron stock by December 2030, representing a 110% total return from current levels at an annualized rate of around 11%, assuming 7% revenue CAGR, 37.3% net income margins, and around 8% EPS CAGR through the forecast window.
At roughly 16.6x 2026 earnings estimates, with a 17% EPS acceleration building for 2027 and a pipeline carrying unpriced optionality across gMG, PNH, melanoma, and geographic atrophy, the 110% total return implied by TIKR’s mid case makes Regeneron stock undervalued for investors with the patience to let the earnings inflection arrive.
The central question is not whether Regeneron’s pipeline has value. It is how much of the pipeline converts before the market loses patience with the gap between R&D spend and revenue.
What Has to Go Right
- EYLEA HD conversion sustains high-single-digit quarterly volume growth as EYLEA 2mg declines, keeping the retinal franchise stable while biosimilar pressure peaks in H2 2026
- Cemdisiran receives FDA approval in Q4 2026 and captures share in a gMG market expected to more than double to over $12 billion in annual net sales by 2032
- Fianlimab plus Libtayo delivers positive Phase 3 PFS data in first-line metastatic melanoma in H1 2026, opening a credible second oncology revenue line and expanding the Libtayo $425 million Q4 2025 quarterly run rate materially
- The Sanofi development balance reaches full repayment by mid-2026, adding approximately $1.2 billion annualized to Sanofi collaboration revenue recognition from H2 2026 forward
- PNH Phase 3 (ACCESS-1 Cohort B) reads out in Q4 2026 with cemdisiran plus pozelimab delivering best-in-class LDH normalization versus eculizumab, derisking the $3 billion global PNH addressable market
What Could Go Wrong
- EYLEA 2mg declines accelerate faster than EYLEA HD can absorb, with multiple biosimilar entrants compressing the retinal franchise below the consensus $15.75 billion 2026 revenue estimate
- Fianlimab plus Libtayo fails to differentiate versus pembrolizumab on PFS, leaving Libtayo a second-tier oncology product rather than a blockbuster that justifies its pipeline premium
- Cemdisiran gMG uptake is slower than modeled given competition from FcRn inhibitors like Vyvgart, which already have physician familiarity and patient adherence in the advanced therapy segment
- R&D expense of $5.9 billion to $6.1 billion guided for 2026 continues suppressing near-term EPS even as pipeline investments build long-term value, extending the timeline before the multiple re-rates
- MFN pricing commitments under the Trump administration deal limit pricing power on future product launches and DUPIXENT indications, capping revenue upside relative to consensus estimates
Should You Invest in Regeneron Pharmaceuticals, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up REGN stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Regeneron Pharmaceuticals, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze REGN stock on TIKR for Free →
